DAVAOnc's profile picture. DAVA Oncology is a strategic consulting company committed to delivering high quality oncology education and expanding access novel cancer therapies.

DAVA Oncology

@DAVAOnc

DAVA Oncology is a strategic consulting company committed to delivering high quality oncology education and expanding access novel cancer therapies.

DAVA Oncology reposted

@DAVAOnc Academia without friends at meetings is like Bermuda without sunshine Why would you want it? 🌞 Grateful for all I’ve learned from these friends. #DAVAGI

CentralParkWMD's tweet image. @DAVAOnc  Academia without friends at meetings is like Bermuda without sunshine Why would you want it? 🌞 Grateful for all I’ve learned from these friends. #DAVAGI
CentralParkWMD's tweet image. @DAVAOnc  Academia without friends at meetings is like Bermuda without sunshine Why would you want it? 🌞 Grateful for all I’ve learned from these friends. #DAVAGI
CentralParkWMD's tweet image. @DAVAOnc  Academia without friends at meetings is like Bermuda without sunshine Why would you want it? 🌞 Grateful for all I’ve learned from these friends. #DAVAGI
CentralParkWMD's tweet image. @DAVAOnc  Academia without friends at meetings is like Bermuda without sunshine Why would you want it? 🌞 Grateful for all I’ve learned from these friends. #DAVAGI

DAVA Oncology reposted

Day 3 of @DAVAOnc GI malignancies summit is in the books. Had to snap a pic with the maestro @vinaykjain17 who makes this and many other great events happen in the oncology space! #livertwitter

pgholam's tweet image. Day 3 of @DAVAOnc GI malignancies summit is in the books. Had to snap a pic with the maestro @vinaykjain17 who makes this and many other great events happen in the oncology space! 

#livertwitter

DAVA Oncology reposted

Nice to see friends, mentors and industry partners to embark on more trials in PDAC. @utswcancer

Can HDAC inhibitors expand treatment options in PDAC? Early data: ivaltinostat + chemo (ORR 25%, mOS 11.7 mo) and entinostat + IO (ORR 11%). Discussed by @Salthecancerguy @UTSW #DAVAGI

DAVAOnc's tweet image. Can HDAC inhibitors expand treatment options in PDAC? Early data: ivaltinostat + chemo (ORR 25%, mOS 11.7 mo) and entinostat + IO (ORR 11%). Discussed by @Salthecancerguy @UTSW #DAVAGI
DAVAOnc's tweet image. Can HDAC inhibitors expand treatment options in PDAC? Early data: ivaltinostat + chemo (ORR 25%, mOS 11.7 mo) and entinostat + IO (ORR 11%). Discussed by @Salthecancerguy @UTSW #DAVAGI
DAVAOnc's tweet image. Can HDAC inhibitors expand treatment options in PDAC? Early data: ivaltinostat + chemo (ORR 25%, mOS 11.7 mo) and entinostat + IO (ORR 11%). Discussed by @Salthecancerguy @UTSW #DAVAGI
DAVAOnc's tweet image. Can HDAC inhibitors expand treatment options in PDAC? Early data: ivaltinostat + chemo (ORR 25%, mOS 11.7 mo) and entinostat + IO (ORR 11%). Discussed by @Salthecancerguy @UTSW #DAVAGI


DAVA Oncology reposted

Delighted to be back in Bermuda 🏝️ for @DAVAOnc GI Malignancies Global Summit - sharing updates on new vaccine and immuno-oncology strategies for patients with colorectal and pancreatic cancer 🌍🎗️🧬

DanielHaldarMD's tweet image. Delighted to be back in Bermuda 🏝️ for @DAVAOnc GI Malignancies Global Summit - sharing updates on new vaccine and immuno-oncology strategies for patients with colorectal and pancreatic cancer 🌍🎗️🧬
DanielHaldarMD's tweet image. Delighted to be back in Bermuda 🏝️ for @DAVAOnc GI Malignancies Global Summit - sharing updates on new vaccine and immuno-oncology strategies for patients with colorectal and pancreatic cancer 🌍🎗️🧬

DAVA Oncology reposted

Excited to have these trials available for our patients! @AdventHealthCFL @drzakoncology

ACTION & RESTORE trials take exercise beyond survivorship, testing whether aerobic training during adjuvant therapy influences both clinical outcomes & biological remodeling in colon cancer. @Dr_M_Tejani @AdventHealthCFL #DAVAGI

DAVAOnc's tweet image. ACTION & RESTORE trials take exercise beyond survivorship, testing whether aerobic training during adjuvant therapy influences both clinical outcomes & biological remodeling in colon cancer. @Dr_M_Tejani @AdventHealthCFL #DAVAGI
DAVAOnc's tweet image. ACTION & RESTORE trials take exercise beyond survivorship, testing whether aerobic training during adjuvant therapy influences both clinical outcomes & biological remodeling in colon cancer. @Dr_M_Tejani @AdventHealthCFL #DAVAGI
DAVAOnc's tweet image. ACTION & RESTORE trials take exercise beyond survivorship, testing whether aerobic training during adjuvant therapy influences both clinical outcomes & biological remodeling in colon cancer. @Dr_M_Tejani @AdventHealthCFL #DAVAGI
DAVAOnc's tweet image. ACTION & RESTORE trials take exercise beyond survivorship, testing whether aerobic training during adjuvant therapy influences both clinical outcomes & biological remodeling in colon cancer. @Dr_M_Tejani @AdventHealthCFL #DAVAGI


DAVA Oncology reposted

Mayo Clinic, MD Anderson, Stanford and U Miami representing NETs at #DavaOnc Day 3 of 4 done!! @DAVAOnc

AmanChauhanMD's tweet image. Mayo Clinic, MD Anderson, Stanford and U Miami representing NETs at #DavaOnc Day 3 of 4 done!! @DAVAOnc

DAVA Oncology reposted

Ending @DAVAOnc GI malignancies on a high note with a session on liver metastases and locally advanced #HCC moderated by @docamitgs @sepideh_gholami #livertwitter

pgholam's tweet image. Ending @DAVAOnc GI malignancies on a high note with a session on liver metastases and locally advanced #HCC moderated by @docamitgs 

@sepideh_gholami 

#livertwitter

DAVA Oncology reposted

The very last @DAVAOnc summit on GI malignancies is underway. Congratulations to @vinaykjain17 and the DAVA team for another tour de force. Over 170 talks in 4 days. Lots of fruitful interactions and learning! #DAVAGI

pgholam's tweet image. The very last @DAVAOnc summit on GI malignancies is underway.

Congratulations to @vinaykjain17 and the DAVA team for another tour de force. 

Over 170 talks in 4 days. Lots of fruitful interactions and learning! 

#DAVAGI

The 2025 DAVA Bermuda GI Summit has successfully concluded. We deeply appreciate the contributions of all attendees for their expert knowledge, thoughtful discussions, and active participation. #DAVAGI

DAVAOnc's tweet image. The 2025 DAVA Bermuda GI Summit has successfully concluded. We deeply appreciate the contributions of all attendees for their expert knowledge, thoughtful discussions, and active participation. #DAVAGI
DAVAOnc's tweet image. The 2025 DAVA Bermuda GI Summit has successfully concluded. We deeply appreciate the contributions of all attendees for their expert knowledge, thoughtful discussions, and active participation. #DAVAGI
DAVAOnc's tweet image. The 2025 DAVA Bermuda GI Summit has successfully concluded. We deeply appreciate the contributions of all attendees for their expert knowledge, thoughtful discussions, and active participation. #DAVAGI
DAVAOnc's tweet image. The 2025 DAVA Bermuda GI Summit has successfully concluded. We deeply appreciate the contributions of all attendees for their expert knowledge, thoughtful discussions, and active participation. #DAVAGI

Gastric cancer with peritoneal metastases (20–45% cases; OS 3–4 mountreated) remains difficult to treat. @Jenny_J_Li @MDAndersonNews reviewed IP chemo approaches (HIPEC, NIPEC, PIPAC); early trials show promise but remain investigational. #DAVAGI

DAVAOnc's tweet image. Gastric cancer with peritoneal metastases (20–45% cases; OS 3–4 mountreated) remains difficult to treat. @Jenny_J_Li @MDAndersonNews reviewed IP chemo approaches (HIPEC, NIPEC, PIPAC); early trials show promise but remain investigational. #DAVAGI
DAVAOnc's tweet image. Gastric cancer with peritoneal metastases (20–45% cases; OS 3–4 mountreated) remains difficult to treat. @Jenny_J_Li @MDAndersonNews reviewed IP chemo approaches (HIPEC, NIPEC, PIPAC); early trials show promise but remain investigational. #DAVAGI
DAVAOnc's tweet image. Gastric cancer with peritoneal metastases (20–45% cases; OS 3–4 mountreated) remains difficult to treat. @Jenny_J_Li @MDAndersonNews reviewed IP chemo approaches (HIPEC, NIPEC, PIPAC); early trials show promise but remain investigational. #DAVAGI
DAVAOnc's tweet image. Gastric cancer with peritoneal metastases (20–45% cases; OS 3–4 mountreated) remains difficult to treat. @Jenny_J_Li @MDAndersonNews reviewed IP chemo approaches (HIPEC, NIPEC, PIPAC); early trials show promise but remain investigational. #DAVAGI

Starting Now: Peritoneal Mets and Appendiceal Cancer Moderated by: @vinaykjain17 #DAVAGI

DAVAOnc's tweet image. Starting Now: Peritoneal Mets and Appendiceal Cancer 
Moderated by: @vinaykjain17
#DAVAGI

EpCAM is overexpressed in GI cancers. Dr. Andrew Coveler @FredHutch highlighted KK-2269 & BA3182. KK-2269 (EpCAM–CD40) showed preclinical synergy w/ docetaxel; trials ongoing. BA3182 (EpCAM–CD3 CAB, n=39) showed manageable safety & favorable SC PK vs IV. #DAVAGI

DAVAOnc's tweet image. EpCAM is overexpressed in GI cancers. Dr. Andrew Coveler @FredHutch highlighted KK-2269 & BA3182. KK-2269 (EpCAM–CD40) showed preclinical synergy w/ docetaxel; trials ongoing. BA3182 (EpCAM–CD3 CAB, n=39) showed manageable safety & favorable SC PK vs IV. #DAVAGI
DAVAOnc's tweet image. EpCAM is overexpressed in GI cancers. Dr. Andrew Coveler @FredHutch highlighted KK-2269 & BA3182. KK-2269 (EpCAM–CD40) showed preclinical synergy w/ docetaxel; trials ongoing. BA3182 (EpCAM–CD3 CAB, n=39) showed manageable safety & favorable SC PK vs IV. #DAVAGI
DAVAOnc's tweet image. EpCAM is overexpressed in GI cancers. Dr. Andrew Coveler @FredHutch highlighted KK-2269 & BA3182. KK-2269 (EpCAM–CD40) showed preclinical synergy w/ docetaxel; trials ongoing. BA3182 (EpCAM–CD3 CAB, n=39) showed manageable safety & favorable SC PK vs IV. #DAVAGI
DAVAOnc's tweet image. EpCAM is overexpressed in GI cancers. Dr. Andrew Coveler @FredHutch highlighted KK-2269 & BA3182. KK-2269 (EpCAM–CD40) showed preclinical synergy w/ docetaxel; trials ongoing. BA3182 (EpCAM–CD3 CAB, n=39) showed manageable safety & favorable SC PK vs IV. #DAVAGI

Starting Now: Antibody-drug Conjugates Moderated by: @kanwal_raghav @MDAndersonnews #DAVAGI

DAVAOnc's tweet image. Starting Now: Antibody-drug Conjugates
Moderated by: @kanwal_raghav @MDAndersonnews
#DAVAGI

CCNE1 amplification (~4–10% of esophagogastric cancers) is linked to CIN, poor prognosis & resistance. At #DAVAGI, @RyanMoyMDPhD @columbiacancer discussed PKMYT1 inhibition with lunresertib(RP-6306), showing preclinical activity & synergy with anti-PD1.

DAVAOnc's tweet image. CCNE1 amplification (~4–10% of esophagogastric cancers) is linked to CIN, poor prognosis & resistance. At #DAVAGI, @RyanMoyMDPhD @columbiacancer discussed PKMYT1 inhibition with lunresertib(RP-6306), showing preclinical activity & synergy with anti-PD1.
DAVAOnc's tweet image. CCNE1 amplification (~4–10% of esophagogastric cancers) is linked to CIN, poor prognosis & resistance. At #DAVAGI, @RyanMoyMDPhD @columbiacancer discussed PKMYT1 inhibition with lunresertib(RP-6306), showing preclinical activity & synergy with anti-PD1.
DAVAOnc's tweet image. CCNE1 amplification (~4–10% of esophagogastric cancers) is linked to CIN, poor prognosis & resistance. At #DAVAGI, @RyanMoyMDPhD @columbiacancer discussed PKMYT1 inhibition with lunresertib(RP-6306), showing preclinical activity & synergy with anti-PD1.
DAVAOnc's tweet image. CCNE1 amplification (~4–10% of esophagogastric cancers) is linked to CIN, poor prognosis & resistance. At #DAVAGI, @RyanMoyMDPhD @columbiacancer discussed PKMYT1 inhibition with lunresertib(RP-6306), showing preclinical activity & synergy with anti-PD1.

At #DAVAGI, @rutikamehtaMD presented utility of ctDNA MRD testing in gastric/upper GI cancers: persistence/rise predicts recurrence. ctDNA detects recurrence upto 3.5 mo before imaging. In surveillance, positivity→81% recurrence, mRFS 6 mo; negativity→13.5% recurrence, NR mRFS.

DAVAOnc's tweet image. At #DAVAGI, @rutikamehtaMD presented utility of ctDNA MRD testing in gastric/upper GI cancers: persistence/rise predicts recurrence. ctDNA detects recurrence upto 3.5 mo before imaging. In surveillance, positivity→81% recurrence, mRFS 6 mo; negativity→13.5% recurrence, NR mRFS.
DAVAOnc's tweet image. At #DAVAGI, @rutikamehtaMD presented utility of ctDNA MRD testing in gastric/upper GI cancers: persistence/rise predicts recurrence. ctDNA detects recurrence upto 3.5 mo before imaging. In surveillance, positivity→81% recurrence, mRFS 6 mo; negativity→13.5% recurrence, NR mRFS.
DAVAOnc's tweet image. At #DAVAGI, @rutikamehtaMD presented utility of ctDNA MRD testing in gastric/upper GI cancers: persistence/rise predicts recurrence. ctDNA detects recurrence upto 3.5 mo before imaging. In surveillance, positivity→81% recurrence, mRFS 6 mo; negativity→13.5% recurrence, NR mRFS.

Starting Now: Emerging Approaches to Increase IO Efficacy in GE Junction Tumors Moderated by: Dr. Manish Shah @WeillCornell #DAVAGI

DAVAOnc's tweet image. Starting Now: Emerging Approaches to Increase IO Efficacy in GE Junction Tumors
Moderated by: Dr. Manish Shah @WeillCornell
#DAVAGI

Cancer-driven vagal hyperactivation may contribute to cachexia. Dr. @drsmags (@MDAndersonNews) discusses vagal blockade, which reduced cachexia and improved survival in PDAC models. Trials are planned to test QOL outcomes. #DAVAGI

DAVAOnc's tweet image. Cancer-driven vagal hyperactivation may contribute to cachexia. Dr. @drsmags (@MDAndersonNews) discusses vagal blockade, which reduced cachexia and improved survival in PDAC models. Trials are planned to test QOL outcomes. #DAVAGI
DAVAOnc's tweet image. Cancer-driven vagal hyperactivation may contribute to cachexia. Dr. @drsmags (@MDAndersonNews) discusses vagal blockade, which reduced cachexia and improved survival in PDAC models. Trials are planned to test QOL outcomes. #DAVAGI
DAVAOnc's tweet image. Cancer-driven vagal hyperactivation may contribute to cachexia. Dr. @drsmags (@MDAndersonNews) discusses vagal blockade, which reduced cachexia and improved survival in PDAC models. Trials are planned to test QOL outcomes. #DAVAGI

In Locally Advanced Pancreatic Cancer (LAPC), PANOVA-3 showed TTF + gem-nab-pacimproved mOS and pain-free survival, though PFS and ORR were similar. Dr. @MPishvaian (@hopkinskimmel) notes device was well tolerated; biomarker work ongoing. #DAVAGI

DAVAOnc's tweet image. In Locally Advanced Pancreatic Cancer (LAPC), PANOVA-3 showed TTF + gem-nab-pacimproved mOS and pain-free survival, though PFS and ORR were similar. Dr. @MPishvaian (@hopkinskimmel) notes device was well tolerated; biomarker work ongoing. #DAVAGI
DAVAOnc's tweet image. In Locally Advanced Pancreatic Cancer (LAPC), PANOVA-3 showed TTF + gem-nab-pacimproved mOS and pain-free survival, though PFS and ORR were similar. Dr. @MPishvaian (@hopkinskimmel) notes device was well tolerated; biomarker work ongoing. #DAVAGI
DAVAOnc's tweet image. In Locally Advanced Pancreatic Cancer (LAPC), PANOVA-3 showed TTF + gem-nab-pacimproved mOS and pain-free survival, though PFS and ORR were similar. Dr. @MPishvaian (@hopkinskimmel) notes device was well tolerated; biomarker work ongoing. #DAVAGI

Zenocutuzumab is a bispecific antibody blocking HER2-HER3 heterodimerization in NRG1+ cancers. Dr. @DrGManji from @ColumbiaMed discussed its activity in pancreatic cancer and recent FDA approval for use in NRG1 fusion+ PDAC. #DAVAGI

DAVAOnc's tweet image. Zenocutuzumab is a bispecific antibody blocking HER2-HER3 heterodimerization in NRG1+ cancers. Dr. @DrGManji from @ColumbiaMed discussed its activity in pancreatic cancer and recent FDA approval for use in NRG1 fusion+ PDAC. #DAVAGI
DAVAOnc's tweet image. Zenocutuzumab is a bispecific antibody blocking HER2-HER3 heterodimerization in NRG1+ cancers. Dr. @DrGManji from @ColumbiaMed discussed its activity in pancreatic cancer and recent FDA approval for use in NRG1 fusion+ PDAC. #DAVAGI
DAVAOnc's tweet image. Zenocutuzumab is a bispecific antibody blocking HER2-HER3 heterodimerization in NRG1+ cancers. Dr. @DrGManji from @ColumbiaMed discussed its activity in pancreatic cancer and recent FDA approval for use in NRG1 fusion+ PDAC. #DAVAGI
DAVAOnc's tweet image. Zenocutuzumab is a bispecific antibody blocking HER2-HER3 heterodimerization in NRG1+ cancers. Dr. @DrGManji from @ColumbiaMed discussed its activity in pancreatic cancer and recent FDA approval for use in NRG1 fusion+ PDAC. #DAVAGI

Starting Now: Targeted Agents for Pancreatic Cancer Moderated by: Dr. Bach Arladan @umiamimedicine #DAVAGI

DAVAOnc's tweet image. Starting Now: Targeted Agents for Pancreatic Cancer 
Moderated by: Dr. Bach Arladan @umiamimedicine
#DAVAGI

Loading...

Something went wrong.


Something went wrong.